Table 2A.

U.S. Food and Drug Administration-approved immune checkpoint inhibitors as of April 2022 for the treatment of lung cancer (32, 33).

Lung Cancer	Immune Checkpoint Inhibitor	Target	Scenario
Non-small cell lung cancer	Pembrolizumab	PD-1 inhibitor	Advanced or metastatic
	Nivolumab	PD-1 inhibitor	Advanced or metastatic Neoadjuvant
	Cemiplimab	PD-1 inhibitor	Advanced or metastatic
	Atezolizumab	PD-L1 inhibitor	Advanced or metastatic Adjuvant
	Durvalumab	PD-L1 inhibitor	Adjuvant
	Ipilimumab and Nivolumab	CTLA-4 inhibitor/PD-1 inhibitor	Advanced or metastatic
Small cell lung cancer	Atezolizumab	PD-L1 inhibitor	Advanced or metastatic
	Durvalumab	PD-L1 inhibitor	Advanced or metastatic
Pleural Mesothelioma	Ipilimumab and Nivolumab	CTLA-4 inhibitor/PD-1 inhibitor	Advanced or metastatic